Pulmonary Arterial Hypertension Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 55+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pulmonary Arterial Hypertension Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension Market.

The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pulmonary Arterial Hypertension treatment therapies with a considerable amount of success over the years.
• Pulmonary Arterial Hypertension companies working in the treatment market are Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others, are developing therapies for the Pulmonary Arterial Hypertension treatment
• Emerging Pulmonary Arterial Hypertension therapies in the different phases of clinical trials are- AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years.
• In March 2026, Zydus Lifesciences Ltd. has secured final approval from the U.S. Food and Drug Administration (FDA) for bosentan tablets for oral suspension, 32 mg. This product is the generic equivalent of Tracleer® tablets for oral suspension (32 mg) and is indicated for the treatment of pulmonary arterial hypertension (PAH). It is primarily prescribed to help improve exercise capacity and slow disease progression in pediatric patients aged three years and older who are diagnosed with idiopathic or congenital PAH.
• In March 2026, United Therapeutics announced that its investigational oral therapy ralinepag achieved the primary endpoint in a late-stage clinical trial for a specific lung disease, leading to a 2.2% rise in the company's shares during premarket trading. The drug helped patients with pulmonary arterial hypertension (PAH) a rare and severe form of high blood pressure affecting the lungs maintain stability for a longer period and reduced the risk of disease progression by 55%.
• In December 2025, tiakis Biotech AG ("tiakis"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe pulmonary and cardiovascular conditions, announced the completion of a comprehensive data package to advance Tiprelestat into a Phase II clinical trial for Pulmonary Arterial Hypertension (PAH) following a preclinical GLP-tox study. Tiprelestat, a first-in-class biological neutrophil elastase inhibitor and BMPR2 amplifier, is being developed as a disease-modifying therapy for PAH, with the potential to reduce underlying inflammation and reverse vascular remodeling associated with this rare and life-threatening disease.
• In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage company focused on developing therapies for cardiopulmonary diseases such as pulmonary arterial hypertension (PAH), announced plans to advance IKT-001 into a global pivotal Phase 3 clinical trial. The study, titled IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is anticipated to begin in the first quarter of 2026.
• In November 2025, Cereno Scientific is seeking FDA approval to initiate a global clinical trial of its oral therapy CS1 a repurposed seizure medication-for patients with pulmonary arterial hypertension (PAH). The company aims to evaluate whether CS1 can enhance quality of life and improve survival in PAH. The trial protocol has been submitted to the FDA, and if approved, the study is expected to start in the first half of 2026 following the standard 30-day regulatory review. The Phase 2b trial will compare CS1 with a placebo at international sites, conducted in partnership with a leading global contract research organization (CRO).
• In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage biopharmaceutical company focused on developing treatments for cardiopulmonary diseases such as pulmonary arterial hypertension (PAH), announced that it plans to advance IKT-001 into a global pivotal Phase 3 clinical trial for PAH. The Phase 3 study, titled IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is expected to begin in the first quarter of 2026.
• In September 2025, AllRock Bio Inc., a clinical-stage biotech company developing therapies for cardiopulmonary and fibrotic diseases, announced a $50 million Series A financing round co-led by Versant Ventures and Westlake BioPartners. The funding will support the advancement of its lead candidate, ROC-101-an oral, first-in-class pan-rho-associated protein kinase (ROCK) inhibitor exclusively licensed from Sanofi-into Phase 2 clinical trials. ROC-101 is being developed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), both life-threatening conditions with poor five-year survival rates of 57% and 38%. By targeting inflammatory, proliferative, and fibrotic remodeling driven by both ROCK1 and ROCK2, ROC-101 holds promise to meet a major unmet need in these patient populations.
• In August 2025, Cereno Scientific's lead candidate, CS1, has been granted FDA Fast Track designation for pulmonary arterial hypertension, acknowledging its promise as a novel and potentially disease-modifying therapy for this rare and severe condition.
• In August 2025, VASTHERA Co., Ltd. announced FDA clearance of its Investigational New Drug (IND) application to begin a Phase 1 trial for VTB-10, a novel candidate for pulmonary arterial hypertension (PAH). Developed via the company's proprietary RedoxizymeTM platform, VTB-10 is a first-in-class small molecule enzyme (Chemzyme) designed to mimic the function of peroxiredoxin (PRX), which is deficient in PAH lesions. Preclinical data showed that VTB-10 not only reversed abnormal vascular remodeling but also restored healthy endothelial function, offering a dual mechanism of action that sets it apart from current treatment options.

Pulmonary Arterial Hypertension Overview
Pulmonary Arterial Hypertension (PAH) is a rare, progressive condition characterized by high blood pressure in the arteries that carry blood from the heart to the lungs. This increased pressure puts a strain on the right side of the heart, making it harder to pump blood and leading to symptoms like shortness of breath, fatigue, chest pain, and swelling in the legs. PAH can be idiopathic, inherited, or associated with other conditions such as connective tissue diseases or congenital heart defects. While there is no cure, treatment options-including medications, oxygen therapy, and lifestyle changes-can help manage symptoms and improve quality of life.

Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:
• TYVASO/TYVASO DPI/TREPROST Inhalation Solution (treprostinil): United Therapeutics/Mochida Pharmaceutical
• OPSYNVI/YUVANCI (macitentan and tadalafil): Johnson & Johnson
• WINREVAIR (sotatercept): Merck
• UPTRAVI (selexipag): Johnson & Johnson/ Nippon Shinyaku
• AV-101: Aerovate Therapeutics
• LTP001: Novartis
• KER-012: Keros Therapeutics
• TPN171H: Vigonvita Life Sciences
• Treprostinil Palmitil: Insmed Incorporated
• Satralizumab (Genetical Recombination): Chugai Pharmaceutical
• Sotatercept: Merck Sharp & Dohme
• Macitentan: Janssen Pharmaceutical
• ACT-293987: Actelion
• GB002 (seralutinib): Gossamer Bio
• Parenteral Treprostinil: Lung Biotechnology PBC
• Ralinepag: United Therapeutics
• Selonsertib: Gilead Sciences
• Sotatercept: Acceleron Pharma
• ubenimex: Eiger BioPharmaceuticals
• Olaparib: AstraZeneca

Pulmonary Arterial Hypertension Route of Administration
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Pulmonary Arterial Hypertension Molecule Type
Pulmonary Arterial Hypertension Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment
• Pulmonary Arterial Hypertension Assessment by Product Type
• Pulmonary Arterial Hypertension By Stage and Product Type
• Pulmonary Arterial Hypertension Assessment by Route of Administration
• Pulmonary Arterial Hypertension By Stage and Route of Administration
• Pulmonary Arterial Hypertension Assessment by Molecule Type
• Pulmonary Arterial Hypertension by Stage and Molecule Type

DelveInsight's Pulmonary Arterial Hypertension Report covers around 55+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pulmonary Arterial Hypertension Therapeutics Market include:
Key companies developing therapies for Pulmonary Arterial Hypertension are - VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, Antlia Bioscience Inc, and others.

Pulmonary Arterial Hypertension Pipeline Analysis:
The Pulmonary Arterial Hypertension pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
• Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Arterial Hypertension Pipeline Market Drivers
• Rising prevalence of Pulmonary Arterial Hypertension worldwide, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Arterial Hypertension Market.

Pulmonary Arterial Hypertension Pipeline Market Barriers
• However, high cost associated with the treatment of Pulmonary Arterial Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Arterial Hypertension Market growth.

Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight
• Coverage: Global
• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers

Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.